NEW DELHI, Sept. 21, 2024 /PRNewswire/ -- Translumina was
incorporated in 2011 as a sales & marketing company
specialising in coronary intervention devices. Since its inception,
the company has successfully established their own manufacturing
capabilities and developed in-house product lines, which are
endorsed by interventional cardiologists worldwide.
"At Translumina, we have a clear ambition to put India on the global map for medical devices
and fulfil our national vision of 'Make in India, Make for the world'. Indian engineering
& innovation will be at the forefront of the medical devices
industry, and the launch of our direct presence in the UAE is a
step in that direction," remarked Gurmit Singh Chugh, Co-Founder and Chairman
of Translumina Therapeutics.
Echoing this sentiment, Punita Sharma
Arora, Co-Founder & Vice-Chairman of Translumina,
added, "We've been present in international markets for more than
five years now and have built up a strong direct presence in
Europe & South Asia. In just the last one year, we have
invested in a direct presence LATAM & SEA, and now with the
addition of the MENA region, we have full conviction that our
comprehensive product portfolio will be able to reach every corner
of the world."
The company's drug-eluting stent technologies have been
developed through a technological collaboration with the
prestigious German Heart Centre, which has led to the development
of groundbreaking medical devices, including the world's
longest-studied DES, with over 10 years of safety and efficacy
data.
Last year, Translumina acquired Blue Medical, a Dutch medical
device company renowned for specializing in drug-coated balloons,
and Lamed, a leading player in the vascular surgery market in
Germany, further enhancing the
company's product offerings. Arjun
Oberoi, Managing Director of Everstone Capital, and board
member at Translumina, reflected, "We partnered with Translumina
with the vision of making it a truly global company. Paired with
the acquisitions of Blue Medical and Lamed, the UAE launch will
enhance our global presence, most importantly in the fast-growing
MENA region."
"We are excited to establish our presence in the UAE, known for
its strategic importance and business innovation," added
Indranil Mukherjee, Group CEO
of Translumina. "This will allow us to better serve the MENA region
while strengthening our global presence and making high-quality
healthcare more accessible."
For further queries, please contact:
Dr. Nancy Chugh
drnancychugh@translumina.in
Photo:
https://mma.prnewswire.com/media/2510677/Translumina_UAE_office.jpg
Logo:
https://mma.prnewswire.com/media/1797972/Translumina_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/translumina-therapeutics-indias-largest-domestic-player-in-the-coronary-stents-market-announces-the-initiation-of-direct-operations-in-the-uae-302254278.html